Cadila Pharmaceuticals today announced the launch of the world’s first aqueous formulation of cholecalciferol, for the treatment of Vitamin D deficiency. It has been developed through totally indigenous research.
The company said its aqueous cholecalciferol injection offers a solution with rapid correction of Vitamin D deficiency in short span of time, and enhances the efficacy of treatment by ensuring painless process.
Key Features of Cadila Pharmaceuticals has announced about its Aqueous Cholecalciferol Injection:
Pharmacokinetics and Pharmacodynamics: Aqueous formulation demonstrates significant improvements in both pharmacokinetic and pharmacodynamics properties of the drug , compared to conventional oil-based cholecalciferol preparations.
Correction of Vitamin D Deficiency: Patients can benefit from a correction of Vitamin D deficiency in short span of time, addressing a critical need for expedited treatment outcomes in many major illnesses.
Painless Administration: The injection is designed for ease of use, providing a painless experience for patients, promoting better compliance with treatment regimens.